Thero2-01S22 in HER2-positive Breast Cancer

NCT05698186 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

320

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Breast Cancer

Interventions

DRUG: Thero2-01S22
DRUG: Placebo
DRUG: Thero2-01S22
DRUG: Placebo

Sponsor

Institut de cancérologie Strasbourg Europe